Analyst Reco. Agenus Inc.

Equities

AGEN

US00847G8042

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.69 ^USD	+40.84%		+120.15%	-29.40%

Apr. 12	Sector Update: Health Care Stocks Slipping Late Afternoon	MT
Apr. 12	Sector Update: Health Care	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	Mar. 18	MT
B. Riley Lowers Agenus' Price Target to $6 From $8, Maintains Buy Rating	Nov. 09	MT
Baird Initiates Agenus at Outperform With $8 Price Target	23-06-06	MT
HC Wainwright Assumes Agenus at Buy With $8 Price Target	23-02-28	MT
EF Hutton Starts Agenus With Buy Rating, Sets Price Target at $8.30	22-12-22	MT
EF Hutton Initiates Agenus With Buy Rating, Price Target is $8.3	22-12-08	MT
SMBC Nikko Starts Agenus at Outperform With $5 Price Target	22-09-28	MT
B. Riley Lowers Agenus' Price Target to $8 from $11, Keeps Buy Rating	22-03-03	MT
HC Wainwright Adjusts Agenus' Price Target to $14 from $12, Reiterates Buy Rating	22-03-02	MT
HC Wainwright Starts Agenus at Buy With $12 Price Target	21-12-16	MT
Agenus : Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 Trial	21-09-17	MT
AGENUS : B. Riley Raises Agenus' PT to $12 from $11, Says Continued Regulatory Progress to Drive Stock Price Performance; Keeps Buy Rating	21-09-07	MT
AGENUS : B. Riley Raises Agenus' PT to $11 from $8, Notes Value Accretive Catalysts; Keeps Buy Rating	21-06-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer